Contraception
Volume 80, Issue 6 , Pages 504-511 , December 2009

Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial

  • Alexander Teichmann

      Affiliations

    • Frauenklinik, Klinikum Aschaffenburg, 63739 Aschaffenburg, Germany
    • ,
  • Dan Apter

      Affiliations

    • Väestöliitto/The Sexual Health Clinic, FIN-00100 Helsinki, Finland
    • ,
  • Janusz Emerich

      Affiliations

    • Institute of Obstetric and Gynecology, Medical University of Gdańsk, 80-402 Gdańsk, Poland
    • ,
  • Klaus Greven

      Affiliations

    • 30459 Hannover, Germany
    • ,
  • Dagmara Klasa-Mazurkiewicz

      Affiliations

    • Institute of Obstetric and Gynecology, Medical University of Gdańsk, 80-402 Gdańsk, Poland
    • ,
  • Giambi B. Melis

      Affiliations

    • Department of Obstetrics and Gynecology, University of Cagliari, 09124 Cagliari, Italy
    • ,
  • Marek Spaczynski

      Affiliations

    • Department of Gynaecology, Obstetrics, and Gynaecologic Oncology, Division of Gynaecological Oncology, Poznan University of Medical Sciences, 61-535 Poznan, Poland
    • ,
  • Gary S. Grubb

      Affiliations

    • Research Headquarters, Wyeth Pharmaceuticals, Collegeville, PA 19426, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 610 353 3599.
    • ,
  • Ginger D. Constantine

      Affiliations

    • Research Headquarters, Wyeth Pharmaceuticals, Collegeville, PA 19426, USA
    • ,
  • Daniele Spielmann

      Affiliations

    • Women's Health, Wyeth Research, 92931 Paris, France
    • Deceased.

Received 25 November 2008 ,Revised 22 May 2009 ,Accepted 22 May 2009.

References 

  1. Loudon NB, Foxwell M, Potts DM, Guild AL, Short RV. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regiment. Br Med J. 1977;2:487–490
  2. Kovacs GT, Rusden J, Evans A. A trimonthly regimen for oral contraceptives. Br J Fam Plann. 1994;19:274–275
  3. Anderson FD, Hait H The Seaonale-301 Study Group. A multicenter, randomized study of an extended cycle of oral contraceptive. Contraception. 2003;68:89–96
  4. Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception. 2004;70:359–363
  5. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception. 2004;69:37–42
  6. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59:357–362
  7. Ferrero S, Abbamonte LH, Giordano M, et al. What is the desired menstrual frequency of women without menstruation-related symptoms?. Contraception. 2006;73:537–541
  8. Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception — an international study on acceptability. Contraception. 2003;67:1–8
  9. Archer DF, Kovalevsky G, Ballagh S, Grubb GS. Effect on ovarian activity of a novel levonorgestrel/ethinyl estradiol oral contraceptive regimen. Fertil Steril [Epub ahead of print, May 4, 2009].
  10. Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and research training in human reproduction. Contraception. 1986;34:253–260
  11. U.S. Food and Drug Administration. Depot medroxyprogesterone, summary basis of approval, medical review. October 27, 1992.
  12. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70:269–275
  13. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regiment of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception. 2006;74:439–445
  14. Birtch RL, Olatunbosun OA, Pierson RA. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception. 2006;73:235–243
  15. Legro RS, Pauli JG, Kunselman AR, et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab. 2008;93:420–429
  16. Schlaff WD, Lynch AM, Hughes HD, Cedars MI, Smith DL. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol. 2004;190:943–951
  17. Archer DF, Maheux R, DelConte A, O'Brien FB North American Levonorgestrel Study Group (NALSG). Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse). Am J Obstet Gynecol. 1999;181:S39–S44
  18. Guilbert E, Boroditsky R, Black A, et al. Canadian Consensus Guideline on Continuous and Extended Hormonal Contraception, 2007. J Obstet Gynaecol Can. 2007;29:S1–S32
  19. Barnhart K, Mirkin S, Grubb G, Constantine G. Return to fertility after cessation of a continuous oral contraceptive. Fertil Steril. 2009;91:1654–1656
  20. Johnson JV, Grubb GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 μg/ethinyl estradiol 20 μg. Contraception. 2007;75:23–26
  21. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003;101:653–661

☆ This study was sponsored by Wyeth Research, Collegeville, PA.

PII: S0010-7824(09)00297-2

doi: 10.1016/j.contraception.2009.05.128

Contraception
Volume 80, Issue 6 , Pages 504-511 , December 2009

Article Tools

* Image Usage & Resolution